At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% BID and Bromfenac 0.09% BID
In Brief
A Phase 4 clinical trial evaluating Ketorolac Tromethamine 0.45% and Bromfenac 0.09% for Post Operative Anterior Chamber Inflammation (Flare). Completed, enrolled 50 participants across 1 site.
Detailed Summary
Approximately 50 patients undergoing cataract surgery will be randomized in an even allocation (1:1) into two treatment groups, either ketorolac 0.45% BID or bromfenac 0.09% BID. Patients will be instructed to begin dosing study medication in the operative eye the day before surgery and continue dosing until day 14. KOWA flare measurements will be performed at postoperative day one and postoperative day 14. The amount of anterior chamber inflammation (flare) will be objectively measured.
Study Details
Timeline
Interventions
Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively